Oxidative stress and left ventricular remodelling after myocardial infarction (Q37338724)

19 August 2017

1 reference

title

Oxidative stress and left ventricular remodelling after myocardial infarction (English)

1 reference

19 August 2017

myocardial infarction

1 reference

0 references

Masatsugu Hori

1

1 reference

PubMed ID

19047340

19 August 2017

Kazuhiko Nishida

series ordinal

2

1 reference

19 August 2017

1 December 2008

1 reference

19 August 2017

Cardiovascular Research

1 reference

19 August 2017

81

1 reference

19 August 2017

3

1 reference

19 August 2017

457-464

1 reference

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications

19 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

The inflammatory response in myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Inflammatory cytokines and postmyocardial infarction remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Myocardial apoptosis and ischemic preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

The importance of manganese superoxide dismutase in delayed preconditioning: involvement of reactive oxygen species and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

The BCL-2 protein family: opposing activities that mediate cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Role of oxidative stress in cardiac hypertrophy and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Death receptors: signaling and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

More than one way to die: apoptosis, necrosis and reactive oxygen damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Cell membrane permeabilization and cellular collapse, followed by loss of dehydrogenase activity: early events in tumour necrosis factor-induced cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

On the involvement of mitochondrial intermembrane junctional complexes in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

The role of apoptosis signal-regulating kinase 1 in cardiomyocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

p38alpha mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Apoptosis signal-regulating kinase 1 is involved not only in apoptosis but also in non-apoptotic cardiomyocyte death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Influence of chronic captopril therapy on the infarcted left ventricle of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Controversies in ventricular remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Clinical practice. Evaluation and management of chronic mitral regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Partial left ventriculectomy for dilated cardiomyopathy: is this an alternative to transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: evidence that dyssynergy might directly induce cardiac remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Clinical practice. Diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

The antioxidant edaravone attenuates pressure overload-induced left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

The role of TGF-beta signaling in myocardial infarction and cardiac remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Carvedilol decreases elevated oxidative stress in human failing myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Allopurinol improves endothelial dysfunction in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

Sphingosine Mediates the Immediate Negative Inotropic Effects of Tumor Necrosis Factor-α in the Adult Mammalian Cardiac Myocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVN335

21 January 2018

Identifiers

DOI

10.1093/CVR/CVN335

1 reference

19 August 2017

1 reference

PubMed ID

19047340